News

A new study led by UCLA researchers has eye-opening findings about low-cost, high-volume unnecessary healthcare. These low-value services may surprise you.

A new study has shocking findings about death rates in heart failure patients enrolled in the Hospital Readmissions Reduction Program.

The key changes the Trump Administration has made that could make it more difficult for consumers to sign up for healthcare coverage.

A commercial health plan analysis by axialHealthcare has interesting findings about funding opioid use disorder treatment plans.

Here’s how health systems can provide patients with ways to improve their overall financial experience as the frustration around high-deductible health plans continue to encourage patient consumerism.

Plans must be able to deploy these five tactics, whether using internal resources or collaborating with a vendor.

A new survey from SAP/Oxford Economics has eye-opening findings about the progress of healthcare’s digital transformations.

Two patient survey studies sponsored by Mallinckrodt reveal findings about patient-reported multiple sclerosis rates.

Allergist Bradley Chipps, MD, shares research on how to fine-tune asthma management strategies.

A Canadian study reveals how clinicians may be able to identify whether asthma will develop in patients as young as age one.

The National Pharmaceutical Council takes issue with ICER’s collaboration with the VA’s PBM. Find out what both camps are saying.

There are tried and true methods to manage through turbulent times, both at the business and personal level. We can apply these methods as healthcare leaders.

FDA granted a new indication to a device that can help reduce the symptoms of withdrawal from the prescription pain drugs.

Because of the impact of Hurricanes Maria and Irma on Puerto Rico’s infrastructure and drug manufacturing, hospitals face an ongoing shortage of IV fluids manufactured there.

A report on a pair of surveys from West reveals interesting findings about patient engagement, prevention, wellness, and quality of care.

: In some cases of healthcare fraud, it’s easy to spot red flags. But in large healthcare organizations, or on the payer end, fraud and waste can be more difficult to detect through layers and layers of data.

New healthcare fraud schemes are emerging. Here are a few of the most noteworthy.

Researchers share surprising findings about PCT-guided therapy in antibiotic management in patients with respiratory infections.

While these types of programs have been in place for several years, it can be difficult to gauge who is using them and how, and whether they are achieving their intended goal.

Fluctuations in drug pricing and medication shortages are among the reasons for rising drug prices. Learn how you can protect your hospital’s bottom line.

A study from West reveals interesting findings about patient engagement, prevention, wellness, and quality of care.

CVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.

FDA approved the first drug in the United States that has a digital ingestion tracking system, which records when the medication was taken.

If your organization is managing a risk-based contract, you are likely working hard to engage physicians. But are you modifying those efforts based on whether physicians are independent or employed? Here’s why you should.

FDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.

The first 2-dose hepatitis B vaccine, which was recently approved by FDA, is expected to be commercially available in early 2018.

FDA warns that this compounded eye drug could lead to a disease that causes blindness.

More education is needed for diabetic patients after a patient died from incorrectly using an insulin pen, according to a new warning from the Institute for Safe Medication Practices.

If it is approved by FDA, an investigational drug to improve glycemic control in patients with type 2 diabetes will likely be a strong competitor to Eli Lilly’s dulaglutide (Trulicity).